The research process was authorized by the individual bioethics committee of the Chinese Center for Disease Control and Avoidance, and all participants provided written knowledgeable consent. Isolation of an Unknown Pathogen In 2009 June, a blood sample in heparin anticoagulant was obtained on day 7 after the onset of illness from an individual from Xinyang Town in Henan Province. Because the cause of the condition was unknown, we designed a technique to isolate the pathogen by inoculating multiple cell lines vunerable to both viral and rickettsial agents, including human cell series HL60; animal cell lines DH82, L929, Vero, and Vero E6; and tick cell series ISE6. The patient’s white cells were used to inoculate cell monolayers.We report the full total results of an ongoing international, multicenter, randomized, open-label, stage 3 study that compares crizotinib treatment with pemetrexed-plus-platinum chemotherapy with respect to efficacy, safety, and patient-reported outcomes in sufferers with previously untreated advanced ALK-positive NSCLC. Methods Patients Patients were eligible for enrollment if indeed they had or cytologically confirmed locally advanced histologically, recurrent, or metastatic nonsquamous NSCLC that was positive for an ALK rearrangement 7,13 and if indeed they had received no previous systemic treatment for advanced disease. Various other eligibility criteria included an age of 18 years or old; measurable disease as assessed based on the Response Evaluation Criteria in Solid Tumors , version 1.114 ; an Eastern Cooperative Oncology Group performance status of 0, 1, or 2 15; and adequate hepatic, renal, and bone marrow function .